BioMarin Goes Shopping

Shares of BioMarin Pharmaceutical are up more than 40% in the last 12 months, and lately all eyes have been on its experimental Morquio syndrome drug. However, today the orphan drugmaker announced a $10 million deal to acquire Zacharon Pharmaceuticals. In this video, our health care analyst discusses this news and touches on last year's success of some prominent orphan drug companies, including NPS Pharmaceuticals and Sarepta .

BioMarin has been a longtime pick of The Motley Fool's Rule Breakers newsletter, and its shares are up more than 180% since it was recommended. If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.

The article BioMarin Goes Shopping originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.